New York State Common Retirement Fund Sells 9,000 Shares of Hologic, Inc. (NASDAQ:HOLX)

New York State Common Retirement Fund lowered its stake in Hologic, Inc. (NASDAQ:HOLX) by 6.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 126,949 shares of the medical equipment provider’s stock after selling 9,000 shares during the quarter. New York State Common Retirement Fund owned 0.06% of Hologic worth $9,152,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Covestor Ltd boosted its holdings in Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after acquiring an additional 133 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares in the last quarter. Brooklyn Investment Group raised its position in shares of Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock worth $82,000 after purchasing an additional 145 shares during the period. Empirical Finance LLC lifted its holdings in shares of Hologic by 1.8% in the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after purchasing an additional 147 shares in the last quarter. Finally, Trivant Custom Portfolio Group LLC increased its stake in Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after purchasing an additional 169 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Ratings Changes

HOLX has been the topic of a number of recent research reports. Jefferies Financial Group assumed coverage on shares of Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price objective on the stock. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Royal Bank of Canada decreased their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Raymond James restated an “outperform” rating and issued a $90.00 target price (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Finally, StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Ten equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.77.

Insider Transactions at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.88% of the stock is owned by corporate insiders.

Hologic Stock Performance

Shares of HOLX stock opened at $65.23 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The firm has a market cap of $14.64 billion, a price-to-earnings ratio of 20.58, a P/E/G ratio of 2.14 and a beta of 0.98. Hologic, Inc. has a 52 week low of $62.69 and a 52 week high of $84.67. The firm’s 50-day simple moving average is $69.62 and its two-hundred day simple moving average is $76.28.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.